In Case You Missed It: Recent News from IASLC

Patient Perspective: Patients With EGFR+ NSCLC May Still Opt for Quality Over Quantity After FLAURA2

Transporting Real-World Evidence Between Countries—Ready to Beam Aboard?

IASLC Names New Chief Science Officer

Proposed Criteria for Tumor Invasion Align with Clinical Factors, Offer Better Predictability, Study Finds

IASLC Calls For Documentation of Tobacco Use in Cancer Clinical Trials

Modified Lung Cancer Screening Eligibility Requirements May Reduce Racial Disparities in Lung Cancer Screening, Treatment

Mesothelioma Patients Experienced Higher Levels of Toxicity on CheckMate743 Regimen Than Reported in Clinical Trials

IASLC Announces Partnerships to Spur Oncogene-Driven Lung Cancer Research, Address Global Challenges in Conquering Thoracic Cancers

Combining SABR with Immunotherapy to Improve Outcomes in Early-Stage NSCLC

Patterns of Failure after PACIFIC: How to Address Disease Recurrence after Chemoradiotherapy and Immunotherapy

In Brief for January 10, 2024